Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 15,552	$ 25,590
General and administrative	14,807	11,845
Acquired in-process research and development	164,617
Total operating expenses	194,976	37,435
Loss from operations	(194,976)	(37,435)
Other income (expense):
Interest and investment income	122	236
Other expense, net	(58)	(101)
Total other income, net	64	135
Net loss	(194,912)	(37,300)
Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs	(24,437)
Net loss attributable to common shareholders	$ (219,349)	$ (37,300)
Net loss per share - basic	$ (24.58)	$ (12.20)
Net loss per share - diluted	$ (24.58)	$ (12.20)
Weighted-average common shares outstanding used in net loss per share - basic	8,925,173	3,058,578
Weighted-average common shares outstanding used in net loss per share - diluted	8,925,173	3,058,578